Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset

Daniel Backenroth(Janssen (Belgium)), Wei Zhou(Broad Institute), Changxia Shao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Emily Castellanos, Tamara Snow, Brian M. Alexander(Brigham and Women's Hospital), Lingkang Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth R. Carson(Flatiron Health (United States)), Garrett M. Frampton(Tech Foundation), Gaurav Singal(Netaji Subhas University of Technology), Guanlin Li, David Fabrizio(Foundation Medicine (United States)), Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University)
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz268.004
Cited by 2

Related Papers

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
|Genome Medicine|2017|3.7k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k